Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 24, 2017
DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM
VANCOUVER, British Columbia and MENLO PARK, Calif., July 24, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer ...
July 24, 2017
Minerva Neurosciences Announces Departure of Directors
WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
July 21, 2017
Aeglea BioTherapeutics Announces Leadership Change
AUSTIN, Texas, July 20, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...
July 21, 2017
TherapeuticsMD to Host Second Quarter Financial Results Conference Call and Webcast on August 3
BOCA RATON, Fla.-- (BUSINESS WIRE) -- TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women’s healthcare company, today announced that it will host a conference call and live ...
July 21, 2017
Pernix Therapeutics Pre-Announces Certain Preliminary Second Quarter 2017 Financial Results
MORRISTOWN, N.J., July 20, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced certain preliminary ...
July 21, 2017
Pernix Commences Refinancing Transactions to Fortify Balance Sheet
MORRISTOWN, N.J., July 20, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today commenced a series ...
July 21, 2017
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 21, 2017 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for ...
July 20, 2017
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
Basel, Switzerland, July 20, 2017 - Basilea Pharmaceutica Ltd. (BSLN.SW) reported today that its license agreement with Pfizer Inc. (PFE) for Basilea`s antifungal Cresemba (isavuconazole), ...
July 20, 2017
Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
REHOVOT, Israel, July 20, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the ...
July 20, 2017
BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
ALAMEDA, Calif.--(BUSINESS WIRE) -- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release ...
July 19, 2017
OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)
NANTES, France, July 19, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company will receive a €9.2 million grant from the ...
July 19, 2017
Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017
BOSTON, July 19, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...
July 19, 2017
BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid® Indications
YAVNE, Israel, July 19, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in ...
July 19, 2017
CymaBay Announces Pricing of Public Offering of Common Stock
NEWARK, Calif., July 19, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
July 19, 2017
Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
ALAMEDA, Calif. -- (BUSINESS WIRE) -- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract ...
July 19, 2017
CTD Holdings Announces First Patient Dosed in Phase I/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C
ALACHUA, FL--(Marketwired - July 19, 2017) - CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of disease, today ...
July 19, 2017
Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan
RA’ANANA, Israel, and NEW YORK, July 19, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
July 19, 2017
Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company
NEW YORK -- (BUSINESS WIRE) -- Immune Pharmaceuticals (IMNP) (“Immune”) today confirmed it is continuing to structure and pursue a spin-off of Cytovia, Inc. (“Cytovia”), its ...
July 18, 2017
Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
BOSTON, July 17, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today positive top-line results from a pivotal Phase 3 clinical study comparing its ...
July 18, 2017
CymaBay Announces Proposed Public Offering of Common Stock
NEWARK, Calif., July 17, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
Page 141 of 153